Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Pezaro

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Internal Medicine Journal|May 13, 2014
Prostate cancer: measuring PSAC Pezaro, H H Woo, I D Davis
Annual Review of Medicine|October 2, 2012
Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancerR Ferraldeschi, C Pezaro, V Karavasilis, et al.
Internal Medicine Journal|April 11, 2016
Author reply 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancerA J Lomax, P Parente, C Gilfillan, et al.
Internal Medicine Journal|March 4, 2015
'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancerA J Lomax, P Parente, C Gilfillan, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2013
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abirateroneD Bianchini, D Lorente, A Rodriguez-Vida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)Y Loriot, D Bianchini, E Ileana, et al.
British Journal of Cancer|June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancerC Pezaro, D Mukherji, N Tunariu, et al.
Clinical Radiology|January 4, 2015
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancerC Pezaro, A Omlin, R Perez-Lopez, et al.
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
British Journal of Cancer|October 15, 2014
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abirateroneD Lorente, A Omlin, R Ferraldeschi, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Internal Medicine Journal|May 13, 2014
Prostate cancer: measuring PSAC Pezaro, H H Woo, I D Davis
Annual Review of Medicine|October 2, 2012
Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancerR Ferraldeschi, C Pezaro, V Karavasilis, et al.
Internal Medicine Journal|April 11, 2016
Author reply 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancerA J Lomax, P Parente, C Gilfillan, et al.
Internal Medicine Journal|March 4, 2015
'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancerA J Lomax, P Parente, C Gilfillan, et al.
European Journal of Cancer (Oxford, England : 1990)|October 1, 2013
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abirateroneD Bianchini, D Lorente, A Rodriguez-Vida, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)Y Loriot, D Bianchini, E Ileana, et al.
British Journal of Cancer|June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancerC Pezaro, D Mukherji, N Tunariu, et al.
Clinical Radiology|January 4, 2015
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancerC Pezaro, A Omlin, R Perez-Lopez, et al.
European Urology|December 4, 2013
Visceral disease in castration-resistant prostate cancerC Pezaro, A Omlin, D Lorente, et al.
British Journal of Cancer|October 15, 2014
Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abirateroneD Lorente, A Omlin, R Ferraldeschi, et al.
Pageof 2